Phase 3 Readout
TKPHF: Phase 3 Topline: A Randomized Controlled Phase III Clinical Study of BL-M07D1 Combined With Pertuzumab Versus Docetax
December 1, 2029 · bl-m07d1. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 1, 2029
- Company
- TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
- Drug
- bl-m07d1
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized Controlled Phase III Clinical Study of BL-M07D1 Combined With Pertuzumab Versus Docetax
- Drug
- bl-m07d1
- Indication
- HER2-positive Breast Cancer